Abstract 2208
Background
There is limited information on the association among complementary medicin (CM), toxicities and overall survival of patients with cancer who receive CM compared with those who do not.
Methods
This is a prospective study including 223 patients collected during 6 months between July 15, 2018 and January 15, 2019 in the department of medical oncology at the Habib Bourguiba university Hospital. All patients were questioned about the concept of taking herbs and botanicals such as gravila and Alinda. We analyzed the demographic data, the toxicities after the consumption of plants as well as the causal link. Then we compared overall survival among those who receive plants versus the non-users.
Results
The average age was 53 years (2-86 years old). There were 152 women and 71 men. 83 patients were illiterate (37.2%). 110 patients had breast cancer (49.3%), the others included colorectal, endometrial, cervical, gastric, ovarian, lung, bladder and head and neck cancers). 97 had metastatic disease (43.4%). 97 patients had taken plants (43.4%), during the medical treatment in 57 cases (58.7%). 60 patients had consumed Alinda (61.8%) and 36 patients had received Graviola (37.1%). 62 women had taken plants against 37 men (χ2 = 1.425, ddl = 1, α = 5%, p = 0.147). 49 patients with metastatic disease had taken plants against 48 with localized cancer (χ2 = 3.468, ddl = 2, α = 5%, p = 0.177). 10 patients have had diarrhea (10.3%), 10 cytolysis (10.3%), 11 cholestasis (11.3%), 15 thrombocytosis (15.4%), 17 leukocytosis (17.5%) and 13 anemia (13.4%). Only leukocytosis, thrombocytosis, and diarrhea were related to plant consumption with p = 0.0001, p = 0.016 and p = 0.014 respectively. Overall survival at 5 years was 67.1%. It was lower in patients consuming the plants (54% vs 83% p = 0.023).
Conclusions
The consumption of Graviola and Alinda was associated with a decrease in the 5 years overall survival (p = 0.023). It was associated with leukocytosis, thrombocytosis, and diarrhoea. This consumption was not statistically different between men and women nor between the localized or metastatic stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
592 - Effects of novel targeted anticancer drugs on cytotoxicity, apoptosis, angiogenesis, EMT, drug resistance and autophagic mechanism
Presenter: Seyma Aydinlik
Session: Poster Display session 1
Resources:
Abstract
3235 - Delineating the mechanisms of alpha 1-3 fucosyltransferase FUT11 in ovarian cancer
Presenter: Qi Chen
Session: Poster Display session 1
Resources:
Abstract
3577 - The tyrosine kinase inhibitor Dasatinib blocks tumor growth, invasion and recurrence potential by interrupting the communication between cancer cells and their surrounding microenvironment in triple negative breast cancer
Presenter: Miriam Nuncia-Cantarero
Session: Poster Display session 1
Resources:
Abstract
4808 - NORE1A induces a feedback termination of TNF signaling by antagonizing TNFR1 through ITCH-mediated destruction complex
Presenter: Jieun Ahn
Session: Poster Display session 1
Resources:
Abstract
1294 - Hsp90 inhibitors enhance the antitumoral effect of osimertinib and overcome osimertinib resistance in non-small-cell cell lung cancer cell models
Presenter: Jordi Codony-Servat
Session: Poster Display session 1
Resources:
Abstract
1559 - Expression of IL-17RA promotes cancer stem-like properties of colorectal cancer cells by Stat3 activation
Presenter: Chih-Yung Yang
Session: Poster Display session 1
Resources:
Abstract
1615 - Adaption of Pancreatic Cancer Cells to AKT1 Inhibition Induces the Acquisition of Cancer Stem-Cell Like Phenotype Through Upregulation of Mitochondrial Functions
Presenter: Hugo Arasanz
Session: Poster Display session 1
Resources:
Abstract
4793 - Bub3 is phosphorylated by the Ataxia-Telangiectasia Mutated Kinase in mitosis and required for activation of the mitotic spindle checkpoint in Breast Cancer
Presenter: Mingming Xiao
Session: Poster Display session 1
Resources:
Abstract
1448 - The regulation of INK4 locus by long non-coding RNAs
Presenter: Yojiro Kotake
Session: Poster Display session 1
Resources:
Abstract
1858 - Vascular Endothelial Growth Factor in Colorectal Cancer Pathology, Survival and Treatment
Presenter: Liz Baker
Session: Poster Display session 1
Resources:
Abstract